Hiroji Iwata

Research interests

Publications

• Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2202809

• Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)02420-5

• First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

  Annals of Oncology · 2021 · 10.1016/j.annonc.2021.05.355

• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)32531-9

• Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

  Cancer Discovery · 2020 · 10.1158/2159-8290.cd-19-1014

• Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)31953-x

• Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

  Annals of Oncology · 2020 · 10.1016/j.annonc.2020.11.011

• Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

  Journal of Clinical Oncology · 2020 · 10.1200/jco.19.02318

• Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30097-x

• Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30689-8

• Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1813904

• Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1914510

• MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

  npj Breast Cancer · 2019 · 10.1038/s41523-018-0097-z

• Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1810527

• Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1809615

• Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

  Annals of Oncology · 2018 · 10.1093/annonc/mdy518

• Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30376-5

• Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1612645

• Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30717-9

• Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(15)00613-0

• Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(15)00551-3

• Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

  Nature Genetics · 2015 · 10.1038/ng.3242

• Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1505270

• Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2006.09.1611

• Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa052306

Current projects

No projects listed.